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Reﬁ ning genetic associations in multiple sclerosis
Genome-wide association studies involve several 
hundred thousand markers and, even when quality 
control is scrupulous, are invariably confounded by 
residual uncorrected errors that can falsely inﬂ ate the 
apparent diﬀ erence between cases and controls (so-
called genomic inﬂ ation).1 As a consequence such 
studies inevitably generate false positives alongside 
genuine associations. By use of Bayesian logic and 
empirical data, the Wellcome Trust Case Control 
Consortium suggested that association studies in 
complex disease should involve at least 2000 cases 
and 2000 controls, at which level they predicted that 
p values of less than 5×10–7 would more commonly 
signify true positives than false positives.2 
cannot be drawn conﬁ dently without a placebo-
controlled (sham surgery) trial, the ethics of which are 
debatable and which might not be practical because 
stimulation eﬀ ects might prevent blinding. A study 
that compares DBS with the eﬀ ects of implanted 
but temporarily inactivated electrodes could further 
diﬀ erentiate the eﬀ ects of surgery versus stimulation. 
Additionally, the test battery used in this study, 
although practical, was restricted, particularly in terms 
of the executive functions that were assessed. Owing to 
the stringent selection criteria (no current or previous 
major psychiatric illness or cognitive impairment), the 
rates of serious psychiatric and cognitive adverse events 
in this study are not trivial. Indeed, the rates of serious 
psychiatric adverse events (and marked cognitive decline 
as per Mattis dementia rating scale score) are high for 
such a short (6-month) follow-up interval in a highly 
selected sample when the typical incidence of serious 
psychiatric and cognitive changes in patients with PD 
over a year are considered.
The results of this study, like those of other hitherto 
unsuccessful investigations, fail to ﬁ nd a signiﬁ cant 
association between neurobehavioural changes and 
changes in drug dose, but the authors did not examine 
the potential role of stimulation and other disease and 
demographic parameters (the range of which might 
have been restricted by stringent selection, potentially 
precluding identiﬁ cation of signiﬁ cant correlations). 
Consequently, the identiﬁ cation of risk factors for 
neurobehavioural decline after DBS in a minority of 
patients is elusive. 
The initial observation in a few small, uncontrolled 
studies that improvements in motor symptoms and 
quality of life might not translate into social readjustment 
deserves urgent investigation.9,10 Future research will 
need to identify the patient-related, medicosurgical, and 
psychosocial factors that preclude gains in occupational, 
interpersonal, familial, and marital functioning in 
some patients, and the barriers to coping and societal 
reintegration. Also, assuming DBS to be safe, should the 
current exclusion criteria for neurobehavioural studies 
be relaxed? This could allow more patients to access to 
a potentially life-improving treatment and enable the 
identiﬁ cation of the risk factors for neurobehavioural 
decline in patients whose selection perhaps more closely 
mirrors clinical practice outside of clinical trials.
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The screening phase of our recent multiple sclerosis 
genome-wide association study3 involved just 
931 trio families and thus fell short of the minimum 
power recommended by the Wellcome Trust Case Control 
Consortium. However, the extension phase of our study 
included 2322 cases, 5418 controls, and 1540 trio families 
(12 360 individuals in total) and identiﬁ ed three markers 
exceeding the consortium’s threshold —rs6897932 in IL7R 
(p=2·94×10–7) and rs12722489 and rs2104286 in IL2RA 
(p=2·96x10–8 and 2·16x10–7 respectively). These markers 
showed modest levels of signiﬁ cance in the screening 
phase of the study (p values 0·0058, 0·0013, and 0·0033, 
respectively). In overlapping4 and independent5 data 
sets, we simultaneously identiﬁ ed association with IL7R 
(rs6897932) through a candidate gene approach. IL2RA 
was suggested as a candidate by its conﬁ rmation as a 
susceptibility gene for type 1 diabetes.2 The extensive 
linkage disequilibrium between rs12722489 and 
rs2104286 in the IL2RA gene meant that it was impossible 
to determine whether one or other locus exerts a primary 
eﬀ ect or whether both inﬂ uence risk.
The three identiﬁ ed loci have several similarities. 
For each the more common (major) allele increases 
susceptibility, and in each case the risk exerted by this 
allele is modest (with odds ratios about 1·2). All three of 
these single-nucleotide polymorphisms have been studied 
in the HapMap cohorts and curiously in each case the risk 
allele is even more common in non-white ethnic groups. 
Because multiple sclerosis is more common in white 
people than in other ethnic groups, this reverse pattern of 
allele frequency is a reminder that these alleles account for 
only a fraction of the heritable inﬂ uences on susceptibility.
To reﬁ ne our understanding of these associations, 
we typed all three variants in an additional 20 708 
individuals in Australia, Belgium, Denmark, Finland, 
France, Germany, Ireland, Italy, the Netherlands, Norway, 
Sardinia, Spain, Sweden, and new samples from the UK 
(webappendix). Together with the 12 360 reported in our 
original screen this provides a total of 33 068 individuals, 
including 11 019 unrelated cases, 13 616 controls and 
2811 trio families (8433 individuals). All individuals 
involved in this study gave informed consent under 
appropriate local ethical approval. Overall genotyping 
eﬃ  ciency was 98·4% for rs6897932, 95·4% for 
rs12722489, and 95·7% for rs2104286. None of the 
three markers showed any signiﬁ cant evidence for 
deviation from Hardy-Weinberg equilibrium in the 
controls although deviation was seen in the cases, as 
expected for genuine associations (webappendix).
In total, 20 population-speciﬁ c cohorts (14 case-control 
and six trio family) were considered. Nominally signiﬁ cant 
association was observed in eight for rs6897932, in nine 
for rs12722489, and in 13 for rs2104286. In all but three 
studies, the risk allele as deﬁ ned in our original screen (ie, 
the major allele at each locus) was over-represented in 
cases. None of these three negative ﬁ ndings (Australia 
and Ireland for rs6897932, and Holland for rs12722489) 
was signiﬁ cant. In short, all signiﬁ cant studies were 
in accordance with the original screen and most in 
which there was no statistically signiﬁ cant association 
implicated the major allele as expected. Results for the 
individual studies are shown in the webappendix.Human DNA sequence
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χ2 p Odds ratio (95% CI)
C allele of rs6897932 (IL7R)
Case-control* 73·14 1·21×10–17 1·200 (1·151–1·252)
Trios† 10·33 1·31×10–03 1·153 (1·057–1·258)
T allele of rs2104286 (IL2RA)
Case-control* 99·12 2·38×10–23 1·247 (1·194–1·302)
Trios† 24·67 6·80×10–07 1·278 (1·160–1·409)
C allele of rs12722489 (IL2RA)
Case-control* 62·84 2·24×10–15 1·234 (1·172–1·300)
Trios† 11.95 5·47×10–04 1·232 (1·094–1·387)
*Based on all 14 case-control cohorts taken together but treating each as a separate stratum in a Cochran-Mantel-
Haenszel test. In total this analysis includes 11 019 cases and 13 616 controls. †This analysis is based on all six cohorts 
of trio families treated together in a transmission-disequilibrium-test analysis. In total this analysis includes 2811 trio 
families (8433 individuals). Primary statistical analysis was done with PLINK,6 and the conditional analysis and 
genotypic testing was done with UNPHASED.7
Table: Association testing in combined cohorts
For HapMap see 
www.hapmap.org/index
See Online for webappendix
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In the control groups, major-allele frequency was 
64–77% for rs6897932, 77–90% for rs12722489, 
and 69–83% for rs2104286. However, applying the 
Breslow-Day test conﬁ rms that there is no evidence of 
heterogeneity of eﬀ ect across the populations for any of 
the markers. Thus, although the frequency of the risk allele 
shows modest variation between white populations, 
the eﬀ ects of these alleles are of undoubted relevance 
(table).6,7
We conﬁ rmed linkage disequilibrium between the 
two polymorphisms in IL2RA (r²=0·5). Conditioning on 
each marker in turn shows that the association seen 
at rs12722489 is entirely a consequence of its linkage 
disequilibrium with rs2104286. This ﬁ nding conﬁ rms that 
rs2104286 (or another single-nucleotide polymorphism 
in linkage disequilibrium with it) is the primary association 
even though it showed less signiﬁ cant association than 
rs12722489 in the original screen. Testing for association 
at the genotypic level conﬁ rms that the homozygous 
risk genotype confers a signiﬁ cantly greater risk than 
the heterozygous genotype for both rs6897932 and 
rs2104286 (webappendix).
This extension analysis illustrates the value of data 
sets that are signiﬁ cantly larger than the minimum 
recommended by the Wellcome Trust Case Control 
Consortium. Although these data convincingly replicate 
these associations, they do not establish these particular 
variants as causative. Fine mapping and functional 
studies will be required.
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